Publications
Detailed Information
TREATMENT-RELATED PNEUMONITIS AND ACUTE ESOPHAGITIS IN NON SMALL-CELL LUNG CANCER PATIENTS TREATED WITH CHEMOTHERAPY AND HELICAL TOMOTHERAPY
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Song, Chang Hoon | - |
dc.contributor.author | Pyo, Hongryull | - |
dc.contributor.author | Moon, Sung Ho | - |
dc.contributor.author | Kim, Tae Hyun | - |
dc.contributor.author | Cho, Kwan Ho | - |
dc.contributor.author | Kim, Dae Woong | - |
dc.date.accessioned | 2012-06-25T06:16:11Z | - |
dc.date.available | 2012-06-25T06:16:11Z | - |
dc.date.issued | 2010-11-01 | - |
dc.identifier.citation | INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS; Vol.78 3; 651-658 | ko_KR |
dc.identifier.issn | 0360-3016 | - |
dc.identifier.uri | https://hdl.handle.net/10371/77396 | - |
dc.description.abstract | Purpose: To assess clinical outcomes and complications in patients with non small-cell lung cancer (NSCLC) treated with helical tomotherapy (HT) with or without chemotherapy. Methods and Materials: Data from 37 NSCLC patients treated between January 2007 and August 2008 were analyzed retrospectively. Twenty-eight patients had Stage HI disease. Concurrent and neoadjuvant chemotherapy was given to 24 and 14 patients, respectively. Radiotherapy was delivered to a total dose of 60-70.4 Gy at 2.0-2.4 Gy per fraction to the gross tumor volume and 50-64 Gy at 1.8-2.0 Gy per fraction to the planning target volume. Results: With a median follow-up of 18 months (range, 6-27 months), 2-year local control and overall survival rates were 63% and 56% for all 37 patients, respectively, and were 78% and 75% for the patients with Stage III disease who received concurrent chemoradiotherapy alone. Acute esophagitis and treatment-related pneumonitis (TRP) >= Grade 3 occurred in 5 and 7 patients, respectively. Four patients died of treatment-related death (TRD) after HT. In univariate analysis, poor performance status, total lung V(5), contralateral lung (CL) V(5), and V(10) were associated with TRD. Only CL V(5) remained significant in the multivariate analysis (p = 0.029). Conclusions: HT with chemotherapy has shown promising clinical outcomes, esophagitis, and TRPs. However, HT has produced a somewhat high rate of fatal pulmonary complications. Our data suggest that CL V(5) should be considered and kept as low as possible (<60%) in addition to the conventional dosimetric factors. (C) 2010 Elsevier Inc. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | ELSEVIER SCIENCE INC | ko_KR |
dc.subject | Non small-cell lung cancer | ko_KR |
dc.subject | Toxicity | ko_KR |
dc.subject | Pneumonitis | ko_KR |
dc.subject | Tomotherapy | ko_KR |
dc.subject | IMRT | ko_KR |
dc.title | TREATMENT-RELATED PNEUMONITIS AND ACUTE ESOPHAGITIS IN NON SMALL-CELL LUNG CANCER PATIENTS TREATED WITH CHEMOTHERAPY AND HELICAL TOMOTHERAPY | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 송창훈 | - |
dc.contributor.AlternativeAuthor | 표홍렬 | - |
dc.contributor.AlternativeAuthor | 문성호 | - |
dc.contributor.AlternativeAuthor | 김태현 | - |
dc.contributor.AlternativeAuthor | 김대웅 | - |
dc.contributor.AlternativeAuthor | 조관호 | - |
dc.identifier.doi | 10.1016/j.ijrobp.2009.08.068 | - |
dc.citation.journaltitle | INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | - |
dc.description.citedreference | Cho KH, 2009, INT J RADIAT ONCOL, V74, P1397, DOI 10.1016/j.ijrobp.2008.10.020 | - |
dc.description.citedreference | Adkison JB, 2008, TECHNOL CANCER RES T, V7, P441 | - |
dc.description.citedreference | Cattaneo GM, 2008, RADIOTHER ONCOL, V88, P310, DOI 10.1016/j.radonc.2008.06.006 | - |
dc.description.citedreference | Sura S, 2008, RADIOTHER ONCOL, V87, P17, DOI 10.1016/j.radonc.2008.02.005 | - |
dc.description.citedreference | Woodford C, 2007, INT J RADIAT ONCOL, V69, P1316, DOI 10.1016/j.ijrobp.2007.07.2369 | - |
dc.description.citedreference | Rice DC, 2007, INT J RADIAT ONCOL, V69, P350, DOI 10.1016/j.ijrobp.2007.03.011 | - |
dc.description.citedreference | Yom SS, 2007, INT J RADIAT ONCOL, V68, P94, DOI 10.1016/j.ijrobp.2006.12.031 | - |
dc.description.citedreference | Schallenkamp JM, 2007, INT J RADIAT ONCOL, V67, P410, DOI 10.1016/j.ijrobp.2006.09.030 | - |
dc.description.citedreference | Wang SL, 2006, INT J RADIAT ONCOL, V66, P1399, DOI 10.1016/j.ijrobp.2006.07.1337 | - |
dc.description.citedreference | Allen AM, 2006, INT J RADIAT ONCOL, V65, P640, DOI 10.1016/j.ijrobp.2006.03.012 | - |
dc.description.citedreference | Liu HH, 2006, INT J RADIAT ONCOL, V65, P561, DOI 10.1016/j.ijrobp.2006.01.033 | - |
dc.description.citedreference | Ramsey CR, 2006, INT J RADIAT ONCOL, V64, P1237, DOI 10.1016/j.ijrobp.2005.11.012 | - |
dc.description.citedreference | Kupelian PA, 2005, INT J RADIAT ONCOL, V63, P1024, DOI 10.1016/j.ijrobp.2005.04.046 | - |
dc.description.citedreference | Yorke ED, 2005, INT J RADIAT ONCOL, V63, P672, DOI 10.1016/j.ijrobp.2005.03.026 | - |
dc.description.citedreference | Rosenzweig KE, 2005, CANCER, V103, P2118, DOI 10.1002/cncr.21007 | - |
dc.description.citedreference | Zatloukal P, 2004, LUNG CANCER-J IASLC, V46, P87, DOI 10.1016/j.lungcan.2004.03.004 | - |
dc.description.citedreference | Kron T, 2004, PHYS MED BIOL, V49, P3675, DOI 10.1088/0031-9155/49/16/014 | - |
dc.description.citedreference | Liu HH, 2004, INT J RADIAT ONCOL, V58, P1268, DOI 10.1016/j.ijrobp.2003.09.085 | - |
dc.description.citedreference | Murshed H, 2004, INT J RADIAT ONCOL, V58, P1258, DOI 10.1016/j.ijrobp.2003.09.086 | - |
dc.description.citedreference | Balog J, 2003, MED PHYS, V30, P3097, DOI 10.1118/1.1625444 | - |
dc.description.citedreference | Lee SW, 2003, INT J RADIAT ONCOL, V56, P996, DOI 10.1016/S0360-3016(03)00127-5 | - |
dc.description.citedreference | Gopal R, 2003, INT J RADIAT ONCOL, V56, P106, DOI 10.1016/S0630-3016(03)00094-4 | - |
dc.description.citedreference | Seppenwoolde Y, 2003, INT J RADIAT ONCOL, V55, P724, DOI 10.1016/S0360-3016(02)03986-X | - |
dc.description.citedreference | Scrimger RA, 2003, AM J CLIN ONCOL-CANC, V26, P70 | - |
dc.description.citedreference | Mehta M, 2001, INT J RADIAT ONCOL, V49, P23 | - |
dc.description.citedreference | Furuse K, 1999, J CLIN ONCOL, V17, P2692 | - |
dc.description.citedreference | Byhardt RW, 1998, INT J RADIAT ONCOL, V42, P469 | - |
dc.description.citedreference | Yamada M, 1998, EUR J CANCER, V34, P71 | - |
dc.description.citedreference | MACKIE TR, 1993, MED PHYS, V20, P1709 | - |
dc.description.citedreference | SCHAAKEKONING C, 1992, NEW ENGL J MED, V326, P524 | - |
dc.description.citedreference | DILLMAN RO, 1990, NEW ENGL J MED, V323, P940 | - |
dc.description.citedreference | TOMODIRECT | - |
dc.description.tc | 3 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.